Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory.
Humans
Child
Adolescent
Iran
/ epidemiology
Measles-Mumps-Rubella Vaccine
/ immunology
Child, Preschool
Antibodies, Viral
/ blood
Measles
/ epidemiology
Male
Female
Young Adult
Seroepidemiologic Studies
Rubella
/ immunology
Mumps
/ immunology
Mass Vaccination
/ statistics & numerical data
Immunoglobulin G
/ blood
Vaccination
/ statistics & numerical data
Enzyme-Linked Immunosorbent Assay
Antibody status
Measles
Mumps
Rubella
Seroprevalence
Vaccine
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
12 Jul 2024
12 Jul 2024
Historique:
received:
04
09
2023
accepted:
05
07
2024
medline:
13
7
2024
pubmed:
13
7
2024
entrez:
12
7
2024
Statut:
epublish
Résumé
The seroprevalence of antibodies against measles, mumps, and rubella (MMR) was evaluated 17 years following a mass vaccination campaign in individuals aged 2 to 22 years who had received routine immunization but were not eligible for an extended immunization program. Samples were acquired from Iran's National Measles Laboratory (NML), with individuals showing positive IgM results excluded. Out of the samples collected in 2020, a random selection of 290 serum samples was chosen, representing individuals between the ages of 2 and 22 years from diverse regions in the country. These samples were subjected to analysis using an enzyme-linked immunosorbent assay (ELISA) to quantify specific IgG antibodies against MMR. The seroprevalence rates of antibodies for measles, mumps, and rubella were determined to be 76.2%, 89.3%, and 76.9%, respectively. Younger age groups exhibited higher seropositivity rates for measles and mumps, whereas the 7- to 11-year-old group demonstrated the highest seropositivity rate for rubella. A reduction in antibody status was observed from younger to older age groups, particularly those aged 17-22. The study unveiled suboptimal antibody levels for measles and rubella, highlighting the necessity for further investigation and potential adjustments to future vaccination strategies. Moreover, the decline in antibody status post-vaccination can accumulate in seronegative individuals over time, elevating the risk of outbreaks.
Sections du résumé
BACKGROUND AND PURPOSE
OBJECTIVE
The seroprevalence of antibodies against measles, mumps, and rubella (MMR) was evaluated 17 years following a mass vaccination campaign in individuals aged 2 to 22 years who had received routine immunization but were not eligible for an extended immunization program.
METHODS
METHODS
Samples were acquired from Iran's National Measles Laboratory (NML), with individuals showing positive IgM results excluded. Out of the samples collected in 2020, a random selection of 290 serum samples was chosen, representing individuals between the ages of 2 and 22 years from diverse regions in the country. These samples were subjected to analysis using an enzyme-linked immunosorbent assay (ELISA) to quantify specific IgG antibodies against MMR.
RESULTS
RESULTS
The seroprevalence rates of antibodies for measles, mumps, and rubella were determined to be 76.2%, 89.3%, and 76.9%, respectively. Younger age groups exhibited higher seropositivity rates for measles and mumps, whereas the 7- to 11-year-old group demonstrated the highest seropositivity rate for rubella. A reduction in antibody status was observed from younger to older age groups, particularly those aged 17-22.
CONCLUSION
CONCLUSIONS
The study unveiled suboptimal antibody levels for measles and rubella, highlighting the necessity for further investigation and potential adjustments to future vaccination strategies. Moreover, the decline in antibody status post-vaccination can accumulate in seronegative individuals over time, elevating the risk of outbreaks.
Identifiants
pubmed: 38997625
doi: 10.1186/s12879-024-09593-6
pii: 10.1186/s12879-024-09593-6
doi:
Substances chimiques
Measles-Mumps-Rubella Vaccine
0
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
696Subventions
Organisme : School of Public Health, Tehran University of Medical Science
ID : 9711410006
Organisme : School of Public Health, Tehran University of Medical Science
ID : 9711410006
Organisme : School of Public Health, Tehran University of Medical Science
ID : 9711410006
Organisme : School of Public Health, Tehran University of Medical Science
ID : 9711410006
Organisme : School of Public Health, Tehran University of Medical Science
ID : 9711410006
Organisme : School of Public Health, Tehran University of Medical Science
ID : 9711410006
Informations de copyright
© 2024. The Author(s).
Références
Honarvar B, Moghadami M, Moattari A, Emami A, Odoomi N, Bagheri Lankarani K. Seroprevalence of anti-rubella and anti-measles IgG antibodies in pregnant women in Shiraz, Southern Iran: outcomes of a nationwide measles-rubella mass vaccination campaign. PLoS ONE. 2013;8(1):e55043.
doi: 10.1371/journal.pone.0055043
pubmed: 23383049
pmcid: 3561451
Zahraei SM, Izadi S, Gouya MM, Hashemi-Shahri SM, Mohammadi M. Immunization coverage of children aged 24–35 months in the Islamic Republic of Iran: a national cluster coverage survey. East Mediterr Health J. 2022;28(2):121–9.
doi: 10.26719/emhj.21.059
pubmed: 35304909
Zahraei SM, Izadi S, Mokhtari-Azad T. Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. Hum Vaccines Immunotherapeutics. 2016;12(12):3118–24.
doi: 10.1080/21645515.2016.1214346
Gonçalves G, Frade J, Nunes C, Mesquita JR, Nascimento MSJ. Persistence of measles antibodies, following changes in the recommended age for the second dose of MMR-vaccine in Portugal. Vaccine. 2015;33(39):5057–63.
doi: 10.1016/j.vaccine.2015.08.057
pubmed: 26319061
Kang HJ, Han YW, Kim SJ, Kim Y-J, Kim A-R, Kim JA, et al. An increasing, potentially measles-susceptible population over time after vaccination in Korea. Vaccine. 2017;35(33):4126–32.
doi: 10.1016/j.vaccine.2017.06.058
pubmed: 28669617
Zahraei SM, Mokhtari-Azad T, Izadi S, Mohammadi M, Sabouri A. Seroprevalence of anti-rubella and anti-measles antibodies in women at the verge of marriage in Iran. Vaccine. 2020;38(2):235–41.
doi: 10.1016/j.vaccine.2019.10.026
pubmed: 31668816
Rezapour R, Dorosti AA, Farahbakhsh M, Azami-Aghdash S, Iranzad I. The impact of the Covid-19 pandemic on primary health care utilization: an experience from Iran. BMC Health Serv Res. 2022;22(1):404.
doi: 10.1186/s12913-022-07753-5
pubmed: 35346175
pmcid: 8960210
MOKHTARI AT, ALAVI MM, Yadegari D, SALEHI M, Shahim F, Zareban I. Epidemiologic survey of documented measles outbreak in Tehran. 2004.
Nejati J, Sargolzaie N, Kiani M, Mahjoob M, Hashemi A. Measles epidemiology in sistan and baluchistan province during April 2006-March 2011. 2013.
Asefzadeh M, Peyrovian B. Epidemiological study of measles in Ghazvin, Islamic republic of Iran, April 1997-April 2003. EMHJ-Eastern Mediterranean Health Journal, 12 (1–2), 14–22, 2006. 2006.
Cortese MM, Jordan HT, Curns AT, Quinlan PA, Ens KA, Denning PM, et al. Mumps vaccine performance among university students during a mumps outbreak. Clin Infect Dis. 2008;46(8):1172–80.
doi: 10.1086/529141
pubmed: 18444852
Schaffzin JK, Pollock L, Schulte C, Henry K, Dayan G, Blog D, et al. Effectiveness of previous mumps vaccination during a summer camp outbreak. Pediatrics. 2007;120(4):e862–8.
doi: 10.1542/peds.2006-3451
pubmed: 17908742
Zahraei S, Gouya M, MOKHTARI AT, Dadras M, Hodaei P, Sabouri A. Descriptive epidemiology of measles in Iran in 1384–7. 2009.
Saffar H, Khalifeloo M, Saffar M-J, Abdollahi A, Parsaei M-R, Ghorbani G-R, et al. Measles and rubella serosusceptibity among population vaccinated with different schedules: the potential impact on measles-rubella elimination in Iran. BMC Infect Dis. 2021;21(1):1–10.
doi: 10.1186/s12879-021-05970-7
Patel MK, Dumolard L, Nedelec Y, Sodha SV, Steulet C, Gacic-Dobo M, et al. Progress toward regional measles elimination—worldwide, 2000–2018. Morb Mortal Wkly Rep. 2019;68(48):1105.
doi: 10.15585/mmwr.mm6848a1
He H, Chen E, Chen H, Wang Z, Li Q, Yan R, et al. Similar immunogenicity of measles–mumps–rubella (MMR) vaccine administrated at 8 months versus 12 months age in children. Vaccine. 2014;32(31):4001–5.
doi: 10.1016/j.vaccine.2014.04.044
pubmed: 24837773
Saffar H, Mousavi SJ, Saffar H, Parsaei M-R, Ghorbani G-R, Saffar MJ. Seroconversion rates following 2 doses of measles-mumps-rubella vaccination given at the ages 12 and 18 months: data for possible additional dose at older age. BMC Immunol. 2022;23(1):1–7.
doi: 10.1186/s12865-021-00465-1
Plans P. New preventive strategy to eliminate measles, mumps and rubella from Europe based on the serological assessment of herd immunity levels in the population. Eur J Clin Microbiol Infect Dis. 2013;32(7):961–6.
doi: 10.1007/s10096-013-1836-6
pubmed: 23417624
Salimi V, Abbasi S, Zahraei SM, Fatemi-Nasab G, Adjaminezhad-Fard F, Shadab A, et al. Implementation of a national measles elimination program in Iran: phylogenetic analysis of measles virus strains isolated during 2010–2012 outbreaks. PLoS ONE. 2014;9(4):e94846.
doi: 10.1371/journal.pone.0094846
pubmed: 24736720
pmcid: 3988093
Xu J, Doyon-Plourde P, Tunis M, Quach C. Effect of early measles vaccination on long-term protection: a systematic review. Vaccine. 2021;39(22):2929–37.
doi: 10.1016/j.vaccine.2021.04.012
pubmed: 33926750
Cohen BJ, Parry RP, Doblas D, Samuel D, Warrener L, Andrews N, et al. Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods. 2006;131(2):209–12.
doi: 10.1016/j.jviromet.2005.08.001
pubmed: 16188328
Tischer A, Gassner M, Richard J-L, Suter-Riniker F, Mankertz A, Heininger U. Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol. 2007;38(3):204–9.
doi: 10.1016/j.jcv.2006.12.017
pubmed: 17289430
Kontio M, Jokinen S, Paunio M, Peltola H, Davidkin I. Waning antibody levels and avidity: implications for MMR Vaccine-Induced Protection. J Infect Dis. 2012;206(10):1542–8.
doi: 10.1093/infdis/jis568
pubmed: 22966129
Paunio M, Hedman K, Davidkin I, Valle M, Heinonen OP, Leinikki P, et al. Secondary measles vaccine failures identified by measurement of IgG avidity: high occurrence among teenagers vaccinated at a young age. Epidemiol Infect. 2000;124(2):263–71.
doi: 10.1017/S0950268899003222
pubmed: 10813152
pmcid: 2810910
Gans HA, Yasukawa LL, Sung P, Sullivan B, DeHovitz R, Audet S, et al. Measles Humoral and cell-mediated immunity in children aged 5–10 years after primary measles immunization administered at 6 or 9 months of age. J Infect Dis. 2013;207(4):574–82.
doi: 10.1093/infdis/jis719
pubmed: 23300162
pmcid: 3549597